4. Adverse event reporting.

Study ID	Additional comments on adverse events
Anh 1989	No comment on adverse events
Anh 1995	No comment on adverse events
Cao 1997	'All 3 drug regimens were well tolerated, and no patient had to discontinue treatment because of adverse effects.' This study also conducted some cardiac monitoring on a non‐randomised subset of patients and does not report any significant differences between groups.
Dondorp 2005	'With the exception of hypoglycaemia there were no serious adverse effects that could be attributed to either treatment.'
Dondorp 2010	'We detected no severe adverse effects that could be attributed directly to drug toxicity. Although one patient treated with artesunate developed a mild urticarial rash, no severe type 1 hypersensitivity reactions were recorded.'
Eltahir 2010	'Following quinine infusion, 12 patients developed tinnitus and one hypoglycaemia. Abdominal pain and nausea were observed in three and four patients in artesunate and quinine groups, respectively.'
Hien 1992	No comment on adverse events
Newton 2003	'Patients treated with quinine consistently developed cinchonism and had a significantly higher frequency of hypoglycemia. One patient had a probable adverse reaction to artesunate. This patient presented with parasitaemia of 31%, a plasma lactate level of 14.5 mmol/L, and a serum bilirubin level of 23 mg/dL and developed a widespread erythematous urticarial rash 17 h after treatment with intravenous artesunate was initiated.'